IMVT Immunovant Inc
Price (delayed)
$16.42
Market cap
$2.79B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.62
Enterprise value
$2.41B
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous
Highlights
Immunovant's debt has shrunk by 92% YoY and by 51% QoQ
IMVT's quick ratio has dropped by 74% year-on-year and by 22% since the previous quarter
IMVT's net income has plunged by 57% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of IMVT
Market
Valuations
Earnings
Shares outstanding
169.86M
Market cap
$2.79B
Enterprise value
$2.41B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$405.21M
Net income
-$382.71M
EBIT
-$382.17M
EBITDA
-$381.48M
Free cash flow
-$325.64M
Per share
Balance sheet
Liquidity
EPS
-$2.62
EPS diluted
-$2.62
Free cash flow per share
-$2.22
Book value per share
$2.4
Revenue per share
$0
TBVPS
$2.86
Total assets
$420.93M
Total liabilities
$68.32M
Debt
$23,000
Equity
$352.62M
Working capital
$344.23M
Debt to equity
0
Current ratio
6.04
Quick ratio
5.52
Net debt/EBITDA
0.98
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-69.8%
Return on equity
-77.9%
Return on invested capital
N/A
Return on capital employed
-108.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMVT stock price
How has the Immunovant stock price performed over time
Intraday
8.03%
1 week
-8.22%
1 month
-20.29%
1 year
-46.65%
YTD
-33.71%
QTD
-3.92%
Financial performance
How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$405.21M
Net income
-$382.71M
Gross margin
N/A
Net margin
N/A
IMVT's net income has plunged by 57% YoY and by 18% from the previous quarter
The operating income has dropped by 52% year-on-year and by 15% since the previous quarter
Growth
What is Immunovant's growth rate over time
Valuation
What is Immunovant stock price valuation
P/E
N/A
P/B
6.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 43% YoY and by 18% QoQ
The equity has contracted by 48% YoY and by 21% from the previous quarter
The stock's price to book (P/B) is 26% less than its last 4 quarters average of 8.6
Efficiency
How efficient is Immunovant business performance
IMVT's return on equity is down by 38% since the previous quarter and by 27% year-on-year
IMVT's return on assets is down by 34% since the previous quarter and by 26% year-on-year
Dividends
What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMVT.
Financial health
How did Immunovant financials performed over time
IMVT's total liabilities has surged by 113% year-on-year and by 2.5% since the previous quarter
IMVT's quick ratio has dropped by 74% year-on-year and by 22% since the previous quarter
Immunovant's debt is 100% lower than its equity
Immunovant's debt has shrunk by 92% YoY and by 51% QoQ
The equity has contracted by 48% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.